REPLIGEN CORP Gain (Loss) on Extinguishment of Debt
REPLIGEN CORP (RGEN) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-02-26
- REPLIGEN CORP gain (loss) on extinguishment of debt for the quarter ending 2020-09-30 was $11.40M.
- REPLIGEN CORP gain (loss) on extinguishment of debt for the quarter ending 2020-06-30 was $0.00.
- REPLIGEN CORP gain (loss) on extinguishment of debt for the quarter ending 2020-03-31 was -$5.70M.
- REPLIGEN CORP gain (loss) on extinguishment of debt for the quarter ending 2019-12-31 was $0.00.
- REPLIGEN CORP gain (loss) on extinguishment of debt for fiscal 2025 was $0.00.
- REPLIGEN CORP gain (loss) on extinguishment of debt for fiscal 2024 was $0.00.
- REPLIGEN CORP gain (loss) on extinguishment of debt for fiscal 2023 was -$12.68M.
- REPLIGEN CORP gain (loss) on extinguishment of debt for fiscal 2022 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month | Gain (Loss) on Extinguishment of Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | ||||
| 2023-12-31 | -$12.68M 10-K · filed 2026-02-26 | ||||
| 2022-12-31 | $0.00 10-K · filed 2025-03-14 | ||||
| 2021-12-31 | $0.00 10-K/A · filed 2024-11-18 | -$13.00K 10-K · filed 2022-02-17 | |||
| 2020-09-30 | $11.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $11.40M derived: sum of 2 quarters · filed 2020-11-05 | $5.70M 10-Q · filed 2020-11-05 | $5.70M derived: sum of 4 quarters · filed 2022-02-17 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | -$5.70M 10-Q · filed 2020-07-30 | -$5.70M derived: sum of 3 quarters · filed 2022-02-17 | -$11.35M derived: sum of 4 quarters · filed 2022-02-17 | |
| 2020-03-31 | -$5.70M 10-Q · filed 2020-05-06 | -$5.70M derived: sum of 2 quarters · filed 2022-02-17 | -$11.35M derived: sum of 3 quarters · filed 2022-02-17 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | -$5.65M derived: sum of 2 quarters · filed 2022-02-17 | -$5.65M 10-K · filed 2022-02-17 | ||
| 2019-09-30 | -$5.65M 10-Q · filed 2020-11-05 | -$5.65M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |